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SUMMARY 
Citicoline, is an active principle that treats one of the most common neuropathies, dementia, 
which in its most severe condition, can develop Alzheimer's. One of the companies that produce 
this drug, it is Ceuber, being the product that generates more benefit. However, with the 
appearance of the Asian generic drug, Ceuber decided to study a process change (US Patent 
3,684,652), with the aim of protecting its market share. 
This study consists of two parts: first, a selection of 18 patents, and it will be selected one, 
the patent that cumplies better the corporative, such as: the elimination of the chromatographic 
column. Subsequently, basic engineering will be developed by scaling two processes in Aspen 
Batch process developer, the current process and the one that best meets the conditions. The 
last one will be simulated in two different ways, within the conditions described by the recipe, one 
with low productivity and the other with high, with the possibility of optimizing equipment in the 
favourable condition... 
The results of this project show that these 18 patents, four require a more exhaustive analysis. 
In this analysis, it is confirmed with notoriety that patent WO2013 / 12893 obtains the best 
productivity. Finally, the simulation corroborates the high productivity of this process, achieving 
the maximum by placing two overlapping reactors, in order to reduce campaign time. 
Basic engineering is not able to determine that the process meets the quality requirements. 
However, the information offered by the patent about quality and the high productivity obtained in 
ASPEN, it promotes to evaluate the process experimentally. 
Keywords: Citicoline, patents, batch plant, basic engineering. 




La citicolina, es un principio activo que trata una de las neuropatías más comunes, la 
demencia, qué en su condición más severa, puede desarrollar Alzheimer. Una de las empresas 
que producen este fármaco es Ceuber, siendo el producto que genera más beneficio. No 
obstante, con la aparición del genérico proveniente de Asia, Ceuber decide estudiar un cambio 
de proceso (US Patent 3,684,652), con el objetivo de proteger su cuota de mercado. 
Este estudio, consta de dos partes: primero, una selección de 18 patentes, en el que se 
elegirá el proceso que mejor se adecúe a unos requisitos corporativos definidos, como por 
ejemplo: la eliminación de la columna cromatográfica. Posteriormente, se desarrollará la 
ingeniería básica escalando dos procesos en Aspen Batch process developer, el proceso actual 
y el que mejor cumple las condiciones. Este último, se simulará de dos maneras distintas, dentro 
de las condiciones descritas por la receta, una con baja productividad y la otra con elevada, con 
la posibilidad de optimizar equipos en la última. 
Los resultados de este proyecto muestran qué de estas 18 patentes, cuatro requieren un 
análisis más exhaustivo. En este análisis, se confirma con notoriedad que la patente WO2013 
/12893obtiene la mejor productividad. Finalmente, la simulación corrobora la elevada 
productividad de este proceso, consiguiendo los máximos colocando dos reactores 
sobrepuestos, con el fin de reducir el tiempo de campaña. 
La ingeniería básica no es capaz de determinar que el proceso cumpla los requisitos de 
calidad. Sin embargo, los datos que ofrece la patente en cuestión de calidad junto con la elevada 
productividad obtenida en ASPEN, promueven a evaluar el proceso experimentalmente. 
Paraules clau: Citicolina, patentes, Batch plant, ingeniería básica.






Ceuber Internacional is a company that was founded in 1959 by Carlos Ceuber, with a view 
to expanding that internationally. In the 60s, the company gains relevance in the Spanish market 
through the commercialization of Anginiuvas, Gamusta and Saicosoma. In the decade of the 70s, 
Ceuber launched its flagship products, it allowed to get recognition in the European market, 
through the Cemicina (Citicoline) and Centro CMP Forte, a series of Nucleotides to treat 
peripheral neuropathies. 
In the 80s, Ceuber positioned itself in the international market by acquiring companies and 
opening subsidiaries throughout the continent and entering in the Latin American market. 
Currently, Ceuber focuses its activity on medicines. However, it also has business areas in other 
sectors such as research, medical devices and active ingredients. 
History of the medication 
In 1972, Ceuber acquired the citicoline molecule from Takuda Pharmaceutics, which will be 
commercialized in 1974 for oral administration, once approved by the Spanish Agency for 
Medicines and Health Products (AEMPS), and in 1978 the injectable medication. Apart from the 
molecule, the laboratory also acquires the process patent (US Patent 3,666,748) to manufacture 
the API and reduce costs. 
At the end of the 1990s, with the discovery of the new process to transform citicoline into a 
new more stable form (Us patent 6,057,301), Ceuber decided to change completely the way to 
develop the drug. Therefore, the company adopts the patent US 3,684,652 to improve the quality 
of the drug, because the previous method had a lot of drawbacks, such as the number of 
reactions, the amount of impurities, low productivity, etc. 
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Nowadays, after more than 30 years commercializing Cemicina, both orally and in an 
injectable form, Ceuber decides to optimize the process to manufacture citicoline, in order to 
ensure its market share because Cemicina is the drug that gives the most benefit, besides the 





 DESCRIPTION OF CITICOLINE 
1.2.1. Chemical description 
Citicoline, also called as cytidine diphosphate-choline (CDP-Choline) or cytidine 5'-
diphosphocholine is defined by the most of patents and almost studies as follows: 
 
 Citicoline is amorphous, hygroscopic powder, which has therapeutic utility, for example, as a 
cerebroprotectant, or a neuroprotectant. In particular, citicoline is beneficial the victims of ischemic 
stroke, head trauma, and, possibly, neurodegenerative disease. In addition, citicoline is used to 
treat unconsciousness resulting from cranial trauma, haemorrhages, cerebral thrombosis, and 
cerebropathies due to atherosclerosis. 
 (Secades J J. CDP-choline: pharmacological and clinical review. Methods Find Exp Clin Pharmacol 1995 
Oct; 17 Suppl B:2-54).. 
  
Figure 1. Company Logo 
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Citicoline is applied as its sodium salt, that is a whitish powder [figure 1] similar to talc, formed 
by crystals of microscopic size between 2.7 and 11 Armstrong, it is composed of two clearly 
identifiable parts: choline and cytidine monophosphate, joined by diphosphate bridge. One of the 
main characteristics of citicoline is its high hygroscopic 
capacity, this causes that the active principle cannot 
be in contact with the environment, a factor that will 
hinder its later storage. To prevent citicoline lost its 
quality as a result of humidity, in 1969 US Pat. No. 
3,687,932 is applied, it is based on the transformation 
of citicoline to monohydrated sodium citicoline.  
The companies that obtained the patent to Takuda, 
including Ceuber, to produce the citicoline 
homogeneously, they agreed that sodium citicoline monohydrate is stable up to a maximum value 
of 5-6% of water, and with a higher percentage, it was not safe the existence of this molecule in 
crystal form, as described above. For this reason, they reached the consensus that, with a higher 
percentage than the one described, the molecule is unstable. The next figure [figure la que sea] 
Figure 3: sodium citicoline 
Figure 2: Chemical structure of citicoline 
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shows the increase of stability after to apply this transformation. The continuous lines represent 
the Apies that are been treated, in a temperature of 17ºC and 70ºC. 
 
 
Figure 4: Humidity effect of citicoline 
 
However, at the end of the nineties an improvement of the previous process appears, it is the 
patent US 6,057,301, which modifies the component until reaching the sodium citicoline 
tetrahydrate. This hyperhydrated form, allows to store the API in conditions more advantageous, 
for instance eliminating the five days to get the purified form to get this crystalize form, being its 
ideal percentage of water up to 12.5%. In this way, the time that elapses until the subsequent 
transformation of the active ingredient to Cemicina. The application of this invention, the only 
concern will be the hygiene of the place of storage: regardless its administration form (oral solution 
or intravenous route). 
The active principle begins to dissolve in critical conditions to be ingested by a human, either 
because it contains acids or in its absence by the temperature at which citicoline is heated, 100ºC. 
As it can be observed in the study [24] and at the same time in the different developments that it 
will be described later, it implies that the maximum temperature during the reactions will be 70 ºC, 
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to avoid its decomposition. During the carrying out of the bibliographic search, it was verified that 
citicoline is distributed (for pharmaceutical use) in a range of purity between 98%, being that 
obtained by the process US3,687,932 at a temperature of 17º during its crystallization, up to 
99.6% through genetic engineering. 
Once the solid is obtained, and transformed into citicoline tetrahydrate, the drug will be 
elaborated, in which its pharmaceutical forms are those that will be seen below, as it is described 
in the SmPC (Summary of product characteristics) 
Oral route: 
Cemicina is a transparent oral solution of pink colour, with smell and flavour of strawberry 
packed in envelope. It comes in packages containing 10 and 30 sachets with 10 ml of oral solution 
each. Each millilitre contains 100 mg of Citicoline (as sodium salt) 
The injectable route: 
Cemicina 500 mg solution for injection comes in clear glass ampoules. Each 4 ml ampoule 
contains 500 mg of Citicoline (as the sodium salt). 
In the following figures, it is shown the difference between the injectable presentation, located 









Figure 5 & 6: Presentations of Cemicina 
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1.2.2. Pharmacological properties 
This pharmaceutical substance is chemically equal to which is found naturally in the human 
organism, that has a vital role for the synthesis of phosphatidyllic acid, an agent of great relevance 
for neurotic growth and neuronal regeneration. 
Phosphatidylcholine is a basic constituent of cells, in particular of cellular membranes. 
Consequently, a continuous synthesis of that, will favourite the good functioning of these 
membranes, and in turn, the cells. This phosphate is the precursor of glycerolcholine, a 
component whose purpose is to give stability and permeability to the membrane.  
Subsequently, the synthesis of glycerolcholine gives rise to choline. This micronutrient is one 
of the few that is able to cross the blood-brain barrier, becoming an important substance for the 
CNS, for the production of acetylcholine. Figure 7 shows that the choline ends its synthesis in 
acetylcholine, one of the most important neurotransmitter (NT) in CNS (central nervous system) 
and it has been demonstrated that’ its absence can produce Alzheimer. 
  
 
Figure 7: Synthesis of citicoline 
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1.2.3. Clinical use of citicoline 
The Citicoline is approved by the Agency of the drug for two therapeutic areas, as indicated 
in the SmPC: 
Treatment of neurological and cognitive disorders associated with cerebrovascular 
accidents (CVA). Cerebrovascular ischemia (ictus), is one of the most important causes this 
dementia. Mild cognitive impairment (MCI), a neurocognitive disorder recognized by the DSM-V 
(international reference manual of mental disorders) as a nosological entity itself., it refers to the 
concern of the patient, an informed person or the doctor because there has been a slight 
deterioration in one or more cognitive areas. MCI can be documented through a standardized 
cognitive assessment and that does not interfere with the capacity for independence in daily 
activities. [reference] 
 LCAs usually appears in smokers, people with dyslipidaemia (hypercholesterolemia and / or 
hypertriglyceridemia), in poor eating habits, high blood pressure, overweight, diabetes and 
sedentarism. Within this population, 1 of every 5 people can suffer MCI, and 20% will develop 
dementia. At times, DCL may be the beginning of the Alzheimer issue. Consequently, the size of 
the population sensitive to taking this drug is very high. 
The effect of citicoline in the 
evolution of MCI and in the Quality 
of life (QoL) of patient was 
evaluated in a double blind 
controlled study, compared with 
placebo. As shown Figure 8 and 
Figure 9, citicoline shows the 
progression the MCI and improve 
their QoL. These results are an example by 
which Citicoline continues to be a drug with a 





Figure 8: Progression of MCI  
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The other indication of Cemicina according to the Smpc is for neurological and cognitive 
disorders associated with cranial 
traumas. Although the most recent 
study, in this indication (COBRIT) not 
shows differences between citicoline and 
placebo, the study had many limitations, 
that difficult to stablish robust 
conclusions. 
On the other hand, it has been 
demonstrated that Cemicina would be 
useful in different pathologies, although 
they are not in the table of product, also known as off-label use. This information is sensitive to 
the patient, for this reason it will not be referenced. 
 
Figure 9: Progression of QoL 




The main objective of this work is to study the effectiveness changing the whole process to 
obtain the citicoline or its sodium salt. 
 
To achieve this objective, a bibliographic search will be applied to obtain different patents 
about its manufacture. After this search, through the conditions stablished by the company, it will 
be selected the patent that best suits the requirements. 
 
 Afterwards, the recipes of these alternatives (the current process and the selected) will be 
scaled using Batch Process Developer of Aspen. Basic engineering of these alternatives will be 
developed and it will be simulated different option and different conditions in the selected process.  
 
Finally, the resulting characteristics will be compared in order to decide which process give 
the best results for the company.
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3. BIBLIOGRAPHIC RESEARCH 
 RESEARCH METHOD 
The search patent was carried out in the succeeding portals: espace.net, patentscope and 
Google patent, using the following words as a key word in the search: "Citicoline Manufacture", 
"Sodium Citicoline Manufacture", "Sodium citicoline process" and "Citicoline process". After this 
research, having obtained a large number of entries; among these entries, it is important to 
highlight that there are entries for the clinical use of Citicoline, the process of the active principle 
to an intermediate form (such as that obtained by Ceuber), the transformation of the drug to its 
respective pharmaceutical forms, and finally the manufacturing process of Citicoline. 
Firstly, it has been established to pre-select patents that show a significant change in the 
equipment used in order to develop citicoline, such as the elimination of chromatographic 
adsorption. However, Ceuber manufactures a total of 38 APIs, therefore, it is necessary to assess 
the number of equipment required and the low feasibility of modifying them for a single active 
ingredient. In the same way, it must be analysed that the final product is citicoline or the sodium 
salt, because it could imply a change in the process for the preparation of the drug, taking into 
account that the 6,057,301 patent is still valid and the company has not considered abandoning 
it. 
Another criterion for selecting a patent, is that it demonstrates a drastic change in the method 
of obtaining the API, for example, the current process needs a culture for biosynthesis unlike 
others that are developed by chemical synthesis, how can be the WO2013 / 128393, which 
obtains a high productivity through the successive reactions. 
Finally, for the definitive selection of the patents, the batch time, the raw materials used and 
the necessary equipment will be valued, but under no circumstances losing the quality of the drug. 
Next, it explains in detail the conditions that the new chosen process must have, in which the final 
result will be the one that best encompasses the different qualities. 
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 CORPORATIVE REQUERIMENTS 
To select the most suitable process for the company, it has been decided that the following 
requirements should be adjusted as much as possible.  
First, it will be described the aspects that affects the productivity directly, these are from 1 to 
5. The optimal process will meet these points, or at least, some changes that imply an 
improvement in manufacturing. Nevertheless, these improvements, cannot lead a worsening in 
the other conditions, such the quality of the drug, the appearance of a high number of secondary 
reactions or impurities, factors that can have an impact, such as the purification, and avoid to 
increase the environmental impact. 
1-Elimination of operations with high cost. The selected patents that aim to reduce 
operating costs as much as possible, focus on eliminating the chromatographic column, because 
it is a process used only in sectors with high added value or increase the yield of the culture. For 
this reason, at the time of pre-selection, there will be at least one process that remove this column. 
2-Maximum adjustment to the equipment available. One of the main characteristics when 
the active ingredients are produced is the type of operation, being in batch. This causes the plant 
equipment is used for more than one developments to manufacture other APIs, therefore, a large 
modification could cause problems in the other processes. 
3-Energy expenditure. This factor is not only linked to the economic issue, it also affects to 
environmental issue, as will be seen in point 9. In a process, it is important to adjust the energetical 
usage as much as possible, adapting the selected patent to avoid loss in efficiency and 
environmental impact.  
4-Time of operation. It is necessary to know the time in each batch, because it is a good 
indicator to approximate the time of the process. In the event that the operating time is high 
(valuating the slowest stage), it can have an impact on a larger amount of workforce (need for 
control, more exhaustive cleaning for each batch), having the same scope and the same 
campaign time, it causes the necessity to obtain an equipment with higher volume. In case that 
all the process is overlapped, it is need a large amount of control. In this way, the optimal process 
will need to have a shorter time or similar to the one used today. 
5-Number of operations: in this case, in the same way as the operating time, an increase in 
the quantity could induce either a greater overall time, caused by the transport of the materials, 
intermediates to other equipment, the time of each procedure, etc or changing the equipment to 
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a high quantity or its volume. Therefore, the theoretical process will have a minimum number of 
operations. 
It should be noted that almost patents that will be selected, they have their origin either in 
China or India. This will cause difficulties in the selection, because these processes are focused 
on cheaper raw materials, number of operations and type of operations, to have a layout as 
optimized as possible. On the other hand, in developed countries workforce is more expensive, 
between 7-9 times in the case of India and 3-5 times in relation to China. Therefore, the 
advantages of the processes as indicated by the patents will be assessed in a different way, 
taking into a consideration the batch time as the productivity of raw materials. In addition, working 
by campaigns is not adequate cause peaks in labour to ensure a final product homogeneous. 
Another difficulty when comparing patents, it will be the legislation, such as waste management, 
the space needed, the cost of electricity, although compared to China the difference is about 10%. 
As can be seen, the chosen process will encompass the best balance between the previous 
points. 
Next, other characteristics are shown apart from the productivity issue. However, if the 
process cannot be adjusted to the requirements that will be seen below, it is automatically 
discarded, because lowering the cost of the process as a result of a loss in medicine quality, it is 
ethically unacceptable. In addition, medicines and active ingredients are governed by quality 
standards, known as Good Manufacturing Practices (GMP). GMPs are described in the European 
Union as follows: 
 
Good manufacturing practice (GMP) describes the minimum standard that a medicines 
manufacturer must meet in their production processes. The European Medicines Agency 
(EMA) coordinates inspections to verify compliance with these standards and plays a key 
role in harmonising GMP activities at European Union (EU) level. 
 
6-Adjustment to the patent 6,057,301. As previously stated, the pharmaceutical laboratory 
purchased a patent to promote the storage of citicoline, which is based on hydration. Then, the 
final product should be either sodium citicoline or the citicoline ion and not another, because it 
would cause the need for a new process. 
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 7-Quality of the active principle. The legislation in the pharmaceutical industry, whether of 
public origin, the EMA in Europe, and the AEMPS in Spain, or by default private legislation to self-
regulate are characterized by having a high demand in the quality standards, unlike the other 
countries that the law is laxer. In this way, the new active principle must have at least the same 
purity as the previous one, not contain dangerous subproducts and in turn that these do not 
provoke a reaction with the future excipients of Cemicina. 
8-Sustainable process. Ceuber in 2005 obtained the ISO 14001, known as Environmental 
Management Systems certification. Also, the current president has as a maximum that the 
company is exemplary in its environmental vision and anticipating the future. Moreover, it is 
expected that the legislation will be more severe in the polluting processes. Consequently, the 
chosen development should not create new waste streams and / or more difficult to manage, such 
as operations that are highly polluting. 
9-Control of the demand. It is important that the new development should be capable to 
manage an increase in demand and not cause stock breakage, because the ability to have the 
drug in a short time in drugstores has a vital importance. In this way, the new process should be 
able to sustain an increase in demand up to 5% in the same campaign time, in the same way as 
the current invention. 
In the next section, after describing some patents, four will be chosen (the current one used 
by Ceuber and three more), in order to analyses more carefully each one, 
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 PATENT PRESELECTION 
In the first search, it was founded 18 patents about the citicoline manufacturing, and in the 
Annex, it could be founded all patents used in this project. To avoid repetitive information, in the 
next paragraphs, it will be shown the preselected patents and another four, as example of discard. 
3.3.1. Patent US3,687,932 
This development is that Ceuber leads today, therefore, this process need to be compared 
with the others, to decide whether obtaining citicoline through other patents is improvable or not. 
This is one of the first methods to manufacture citicoline industrially, because it has its origin in 
the molecule development. In this way, the purpose of this patent is to obtain a stable product 
with a high purity, showing at the same time the great advance that this molecule represents in 
the field of neurology. It should be noted that other aspects are left aside: the economy of the 
process, waste management, etc. Moreover, the process was registered at a time when 
environmental legislation was almost non-existent. Therefore, it should be assumed that in almost 
fifty years, has appears an upgrade in citicoline manufacturing.  
Despite the drawbacks mentioned above, it should be noted that this process has a total 
operating time similar to some contemporary processes and even in a shorter time, highlighting 
the relatively low reaction time, adding that, since the beginning of the application of the patent, 
the company has managed to improve the development in three essential aspects: cost, time and 
quality. However, a significantly improvement will be obtaining eliminating chromatographic 
adsorption and increasing the volume productivity without harming other aspects. 
The adsorption in chromatography column, is based on the ionic interaction (Van der Walls 
forces) between the different phases, the stationary (Dowex resin) and the mobile (solution to be 
separated) in order to the more polar solute, KOH, will flow faster through the resin. 
To carry out this operation properly, the solution containing the API must be poured into the 
column, being adsorbed the API and a part of the solution inside. Next, the column will be washed 
with water, to remove a first part of impurities, but being incapable of modifying the amount of 
citicoline retained in the resin. Finally, acetic acid is flowed, to separate the different products in 
stage, one of that, it is citicoline. 
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In the following images, the operation of this stage is shown in detail, in which each 
component (shown with colours) separates along it. The shown situation, is ideal, therefore, there 
will be a part of citicoline that will be lost at the time of collecting the eluent, in addition the column 




Figure 10. Ideal representation of a chromatography column 
The purpose of this project is to know if news methods are capable to increase the efficiency 
during the citicoline manufacture, for this reason, it is necessary to simulate this process through 
the Aspen with some results obtained in plant, to compare with the preselected processes and 
finally if the acquisition of a new patent is feasible or not. Therefore, this process is preselected. 
3.3.2. Patent WO2013/128393 
The objective of this patent, as described in the summary, is to prepare sodium citicoline with 
high productivity through the chemical synthesis of its products (without biological reactions), in 
which the cultivation stage and the chromatographic adsorption are abandoned because 
impurities are separated by precipitation. In this case, apart from the elimination of the column, 
the high purity of the active principle is also highlighted, being greater than 99% (by HPLC 
analysis), the other point to consider is the reduced time of the chemical reaction. However, being 
a biochemical process, the reaction needs to be done in another space. 
This patent has the advantage of being carried out very effectively, either by the reaction time, 
being less than 7 hours (the maximum according to the recipe), the quantity of raw materials is 
reduced and the detailed operations, despite not being in the current process, are common, such 
as frozen or precipitation reaction; In this aspect the process does not create any inconvenience. 
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However, a possible drawback is that the description does not mention anywhere the issue of the 
elimination of hazardous substances for humans and the environmental impact, factors that are 
found for the optimal process. In short, observing the characteristics, the patent is preselected. 
3.3.3. Patent CN 201410247176 
The purpose of this method is to obtain sodium citicoline by oxalyl chloride. This technique, 
in the same way as the previous procedure, seeks to reduce costs as much as possible, focusing 
the improvement in the following three areas: the reduction in the cost of raw materials, being 
these very easy to obtain; high yield in the reaction, achieving an elevate productivity and the low 
complexity of the operations, that avoids the use of chromatographic adsorption. 
However, the complications that this method presents are: the time in the crystallization, being 
from 24 to 48 hours, unlike the 2 hours in the current process, the final purity of the active principle, 
in this case is 98.5% instead of 99%, a fact that could cause either a change in FT or non-
compliance with GMP or the necessity to do a recrystallization, a factor that would increase the 
overall time in this process. Moreover, it does not mention the environmental impact, nor the 
waste management. 
Once all the aspects have been observed, this process is discarded. Mainly for the number 
of hours that would be needed to achieve the purity of the current API, or another solution would 
be the change in the volume of the equipment, reason that would harm the efficiency during the 
manufacture of the other active ingredients developed by the company, because the equipment 
would not work at the optimum performance for what they were designed. However, this method 
could be interesting to manufacture in areas where the cost of labour is lower, because this 
procedure has been developed for domestic use, that is, in China.  
3.3.4. Patent CN107488603 
The following patent, presents a drastic change with respect to the other, to be manufactured 
by the transformation of the gene, being a process of bioengineering. This process is based on 
the recombination of the gene and its future transformation. This procedure marks an important 
difference with respect to the others, but also presents a long list of drawbacks. 
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The method has a high number of operations, which makes it difficult to applicate, the yield is 
less than 70%, away from the 77% presented by the original process. The culture used in each 
procedure have a single use, being a large expense in materials, a factor to avoid, and the most 
important, the final product is not sodium citicoline in the form of diphosphate, but 
monophosphate, therefore, the active principle is not the same. Finally, although the description 
of the process indicates that its duration is short, it is much greater than the other methods with 
the possibility of being pre-selected. 
With the aspects defined in the previous paragraph, the patent has little viability because it 
does not adapt to the demands of the company for its subsequent development in the plant, 
therefore, the process is discarded. 
3.3.5. Patent CN103849666B 
The next method, can obtain the highest purity index in the 25 processes that has been found, 
obtaining up to 99.8%, as it is commented in the example. The purpose is to obtain sodium 
citicoline by immobilized enzymes. The main advantages of the process, according to the 
description are: the obtaining an active principle suitable for the pharmaceutical industry, a 
product of high stability, the immobilized cytidine can be used repeatedly for its synthesis, easy 
operations to control, a high conversion in the reaction, a low cost together with a low operating 
time and to conclude, environmental sustainability is described, being one of its strengths for the 
ability to recycle raw materials or catalysts. 
In spite of the benefits that the patent refers, the use of chromatographic adsorption, breaks 
the corporative objectives, in the same way, the operations that should be applied, are absolutely 
different to the current process, an example of which are ultrafiltration and spray by ultrasound. 
In addition, the biological reaction requires a high reaction time, being of 26 hours and having 
different raw materials. Consequently, it is discarded.  
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3.3.6. Patent CN102078299A 
This method consists in a variation from the active 
ingredient to achieve the liposomal citicoline [figure]. It is 
developed by reacting CDP-choline with phospholipids, this 
product has the characteristic of providing improvements in 
pharmacology and offers greater ease of storage, with 
respect to the non-hydrated form. Therefore, it would be 
applied only in case to innovate the medicine or want to 
change the patent US 6,057,301. 
  
3.3.7. Patent CN1944661A 
This process is based on the selection of a new solvent and biocatalyst during biosynthesis. 
This development implies a greater ease in the process with a high performance in the most 
expensive operations, such as cultivation, which in this method can be used up to three times, 
with a smaller size in culture, causing lower cost, less impact on the environment and finally, 
higher productivity. On the other hand, the patent has a series of handicaps, such as the 
chromatographic stage and the need to freeze the culture for 5 days at -20 ° C, this operation can 
cause a difficulty in case of breaking stock. 
The 104021105 patent has the same weaknesses during the citicoline manufacture, as the 
Japanese patent. Both processes require the chromatographic step, a high time during the 
cultivation and finally, the need to crystallize the final product. Despite all these drawbacks, it has 
been decided to select this process mainly for one reason, to assess the impact generated by 
the reuse of raw materials: in the economic incomes and the environmental impact. 
3.3.8. Patent CN101538598A 
This patent describes a method for obtaining pure citicoline from the improvement in the 
culture, an operation that causes problems due to the difficulty of recycling materials (substrates), 
the time required and its conversion. In this case, the process is very similar, it has a first part of 
culture, having the next differences: the catalysis is inside the cell, and the purification stage, 
Figure 11. Liposomal ciicoline 
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using a centrifugation, where the pure citicoline will be floating in the fluid. In addition, the patent 
states that no external energy needs to be applied during the reaction, reducing the energy 
expenditure of the process. 
This patent will be selected because the obtaining of citicoline is very similar to the original; 
both in raw materials, number of stages and the method of obtaining the active principle 
(cultivation, reaction and finally separation) with the advantage that the chromatographic step will 
not be used. Finally, the products used as substrate are economical and with a high recycling 
capacity or with a less complex treatment, so that their environmental impact is as low as possible. 
 
It is important to point out that the most innovative processes, those that seek to obtain a 
solution that covers improvements in several areas, either by cost or by their environmental 
impact, sometimes imply an improvement of the molecule, for example in sodium phosphate 
choline cell or in liposome, a component that obtains better results in clinical trials. Another aspect 
to evaluate is that the methods that imply an improvement in the environmental impact are carried 
out through genetic engineering. Consequently, if the improvement of the process is not 
significant, the company should do a rethink if it is viable to maintain the intermediate step to 
citicoline tetrahydrate and at the same time to what extent continue to develop the sodium 
citicoline diphosphate instead of a new form of this API. 
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4. PATENT SELECTION  
 
In this section, are going to be explained the method to select the patent that offers the best 
solution for the company. It is important to note, that the final product is citicoline or sodium 
citicoline, in the main reactions a high yield is obtained and the quality of the final product is inside 
the required margins. Therefore, only those aspects that directly affect productivity will be studied. 
To carry out this analysis, it will be done through the data offered by the four recipes. This 
criterion has been established because the data that comes from the plant, are significantly better 
than the example, because the process is optimized. Therefore, an increase in plant efficiency 
could be translated into each process. 
 ANALYTICAL METHOD 
 
In this section, with the objective to realize a thorough analysis, the results that will show the 
best method, its will be obtained by the next information. 
  1-Productivity of raw materials: In each of the 4 recipes, the references indicated that 
limiting reagent is consumed between 70-90%, either in a single reaction (in the fermentation 
processes) or in successive necessary reactions to obtain the final product (patent WO2013). In 
contrast, biosynthesis reactions require a greater number of components, an example of which 
are substrates or amino acids, causing an increase in the substances that participate in the 
biological reaction 
The calculus of this performance, is made by the next expression: 
 
𝑃𝑟𝑜𝑑𝑢𝑐𝑡𝑖𝑣𝑖𝑡𝑦 =
𝑀𝑎𝑠𝑠  𝑜𝑓 𝑐𝑖𝑡𝑖𝑐𝑜𝑙𝑖𝑛𝑒 𝑜𝑏𝑡𝑎𝑖𝑛𝑒𝑑 𝑏𝑦 𝑡ℎ𝑒 𝑟𝑒𝑐𝑖𝑝𝑒
𝑀𝑎𝑠𝑠 𝑜𝑓 𝑟𝑎𝑤 𝑚𝑎𝑡𝑒𝑟𝑖𝑎𝑙𝑠 𝑢𝑠𝑒𝑑 𝑖𝑛 𝑡ℎ𝑒 𝑟𝑒𝑎𝑐𝑡𝑖𝑜𝑛𝑠
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In the tables of the different processes, it could be found that there are two yields, one taking 
into account the sugar and the other not, the reason for this consideration is the low environmental 
impact that it generates, in addition to have reduced cost. 
To finish, the amount of citicoline used in the calculation is the facilitated by the example, 
having passed through the different stages of purification. 
2-Time of operation: Pharmaceutical processes are characterized for being in discontinuous, 
reason that leads to use different equipment at the same time, action known as overlap. 
Throughout the project it has been commented the short amount of information that is detailed by 
the recipes, for instance the duration in every stage, only commented for the reactions and in an 
approximate way. Consequently, it will be considered that the time of the process is the slowest 
stage (usually the chemical reaction) and productivity time will be realized by the next way: It is 
important to point out that this productivity is evaluated with the same reaction volume, being of 
1 liter in each process. 
 
𝑃𝑟𝑜𝑑𝑢𝑐𝑡𝑖𝑣𝑖𝑡𝑦 𝑡𝑖𝑚𝑒 (𝑃𝑇) =








3-Cost of the products: Finally, it is necessary to know the approximate cost in each 
substance that is involved in the reaction, to assess how influence an improvement in 
performance in the final cost of production. This calculation will serve to guide which process 
needs to invest the most economic resources and not to establish the exact cost per gram. This 
approach has been made looking for the cost of 1Kg of each product, indicating that it will be for 
pharmaceutical use, in case the product is not found, it has been decided that it will have got the 
same cost as the most expensive product that participates in the process and results show the 
cost per gram in the recipe conditions. Logically, the order of compounds in high quantities is 
more economical and is incomparable to the product price from these results. 
On the other hand, the price search has not been evaluated in substances that are recovered, 
because the los is zero, one of these compounds can be the catalysts, the materials present in  
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the different stages of purification such as resin Dowex or activated carbon. These substances 
are highlight in red. 
 
The calculation will be made as follows: 
 
𝐶𝑜𝑠𝑡 =
𝑃𝑟𝑖𝑐𝑒 𝑜𝑓 𝑡ℎ𝑒 𝑚𝑎𝑡𝑒𝑟𝑖𝑎𝑙 𝑢𝑠𝑒𝑑 𝑖𝑛 𝑟𝑒𝑎𝑐𝑡𝑖𝑜𝑛 






When basic engineering is developed, the energy needed to develop the process is unknown, 
the only way is to approximate which stage has more energy necessities than another one. At the 
same time, the approximations in terms of labour cost, number of operations and type of 
operations, in this section it will not be evaluated, because they have already been taken into 
account in the pre-selection and with the results that will be obtained, it is not possible to perform 
correctly. 
 CURRENT PATENT 
The process is based on a single fermentation to obtain the API, with the inconvenience to 
need some expensive operations and in the same time losing a lot of efficiency, according to the 
recipe, these losses is approximately 50%, in particular, during the purification stages.   
Seen the results in the table, they present an unaffordable cost for the company, because the 
product value (a box of 30 envelopes, having each dose one gram) is 48 euros, a factor that 
demonstrates either the impossibility to carry out the manufacture of the API without the process 
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7,38 7,38 41 0,30258 
Choline chloride 24 24 359 8,616 
ATCC 6872 10 10 1 0,01 
Monophosphate 11,6 11,6 10 0,116 
Diphosphate  20 20 10 0,2 
Magnesium sulphate 2,96 NA 
  
Sugar 10 10 0,5 0,005 
Citicoline - 1.3 
  





Yield without sugar (%) 0.80 
  
0 
Productivity time  0.0054    
Table 1: Results of the process 
 
One of the few positive elements of this process is its reaction time; said synthesis requires 
only 4 hours but obtaining a reduced amount of active principle in comparison with the products 
that are necessary to carry out the reaction. Regarding the purification method, it is done in two 
adsorption columns; it is necessary to eliminate a large quantity of impurities disposed in the 
solution, as a result the amount collected is only 20% respect of the obtained in the fermentation. 
Likewise, the operation times are high (in plant), because the process needs to be repeated up 
to three times in the chromatographic column, in order to recover a greater quantity of active 
principle. 
With regard to waste management, this process is only done with organic substances 
(reactants) and a positive point, it is the reutilisation of the product. An example of this are some 
culture compounds and formic acid, which is recovered by evaporation. Moreover, the catalysts 
are recovered through precipitation and subsequent filtering. However, these situations are those  
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that appear in the plant, their recyclability will be considered non-existent, except that their reuse 
is specified in the recipe for elements participating in the reaction, except for the catalysts. 
Finally, the overlap in each of the operations, will inspire the one that is in plant, the reason is 
that this modification is alien to improve the performance of operations (reactions, purifications, 
etc.) and is an important factor to the time to perform a scaling. To calculate the PT, it will be used 
the reaction time, because is the slowest stage in the reaction.  
 PATENT WO2013/128393 
Patent WO2013/128393 is the only process in which citicoline is obtained by chemical 
synthesis. It is based on the same procedure as the previous ones, but with some differences that 
it gets optimal results: high productivity, ease of separation, high purity product, etc. These 
differences are the following: phosphates are not reacted as salts, but instead are found in choline 
chloride, using herein calcium phosphoryl choline chloride (CPCC); the use of N, N'-
Dicyclohexylcarbodiimide (DCC) to condense the CMP, the morpholine to facilitate the 
dissociation of the salts present from the beginning of the reaction and to finish, the use of 
dicarboxylic acids, the use of this acid allows the impurities precipitate quickly and completely, 
one of these precipitates can be calcium oxalate. 
This method of obtaining citicoline, is an application to the pharmaceutical industry of the 
synthesis described in the year 1970, can be found in the following article: 
Synthesis of a Nucleotide Coenzyme, CDP-Choline KIYOMI KIKUGAWA and MOTONOBU ICHINO 
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Figure 12: Chemical synthesis of citicoline 
As regards the operations, the elimination of the impurities causing them to precipitate, implies 
suppressing the chromatographic column, one of the purposes of Ceuber. In order to improve the 
elimination by precipitating compounds present in the solution, a freezing is carried out together 









monophosphate 100,00 133,33 41,00 5,47 
Morpholine 75,00 100,00 82,00 8,20 
DCC 100,00 133,33 359,00 47,87 
CPCC 200,00 266,67 1000,00 266,67 





yield (%) 41,63 
 
Price 
citicoline (€/g) 1,54 
Productivity time 1,174833333 
   
Table 2: Results of the process 
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As it has been announced in the previous section, the table 2 shows the high productivity of 
the process in all its areas, getting according to the recipe about 352.45 g per litter, an amount 
that is not capable to compare between other processes, besides abandoning as laborious stages 
as a 10-hour fermentation or the application of the chromatography column. However, these 
excellent results present significant shortcomings. 
The main problems of this process are the high cost of the substances, such as € 1000 per 
kilo of CPCC, as opposed to choline chloride, with a value of € 359 and is the most expensive 
product in the other inventions. Another drawback to add is the inability to find the morpholidate 
salt of oxalic acid (MSOA), during the search for the price of reagents, no intermediary has been 
found to supply this compound, also this compound at a bibliographic level is only referenced in 
the description of this patent and indirectly in the article referenced above, which means that 
Ceuber must obtain the component, either in the pharmaceutical plant or in the plant responsible 
to produce fine chemicals. 
On the other hand, it also presents problems in terms of the safety of the reagents or 
compounds that are directly involved, these products are: oxalic acid, morpholine and chlorhydric 
acid. However, the laboratory had previously worked with morpholine (US 3,666,748), this gives 
a degree of experience to the company when handling these dangerous substances. Moreover, 
the current process in the intravenous drug, contains traces of chlorhydric acid. As regards the 
other compound (oxalic acid), it is to be assumed that they will be separated in the same way as 
the other patents, such as distillation, condensation, etc. 
Finally, the overlap of this process, it will be dominated by the slowest stage, the reactor. 
Having two reactions in the same recipient, it gives two possibilities to apply that patent, either 
use one reactor with more volume or to use two reactors with less volume. The overlap must have 
taken into a consideration the manufacturing of MSOA. It could be at the same time as the others, 
and it would be established between the faster processes, and better adjust the overlap 
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 PATENT CN200810019854 
The synthesis of the active principle is carried out through choline chloride, CMP and 
phosphates, with a change in the culture in which a better result is obtained than the current one. 
In the following table, each of the reagents involved in obtaining citicoline is shown, without 
taking into account other compounds that do not intervene in the reaction, such as sodium 
hydroxide to adjust the pH. 
Product 
Amount in the 







Choline chloride 60mM 8 359 3,01 
dihydrogen phosphate 0.2 M 23,8 56 1,33 
CMP 30mM 4 41 0,16 
Glucose 0.3 M 54 0,5 0,03 
Magnesium Sulfate 50mM 15 n/A N/A 
KCl 2mM n/A n/A N/A 
Cysteine 2mM 0,24 n/A N/A 
Clay 2800g 187 359 0 
Culture (40g/L) - 40 Unknown 0 
Glucose - 2 67 0,13 
Urea - 1,5 158 0,24 
Potassium dihydrogen 
phosphate - N/A N/A N/A 
MgSO4*7 H2O - N/A N/A N/A 
ZnSO4*7H2O - N/A N/A N/A 
FeSO4*7H2O - N/A N/A N/A 
MgCl*7H20 - N/A N/A N/A 
Biotin - 4 n/A n/A 
 
 Table 3.1: Results of the process 
 




Yield without sugar 5,54 
Price g 4.82 
Productivity time 0.02 
Table 3.2: Yield of the process 
 
Table 3.2 demonstrates the need for the company to make a change in obtaining citicoline, 
this process multiplies the yield, with a cost per gram significantly lower than the current one, 
taking into a consideration that clay has its cost as the most expensive, such as the MSOA in the 
prior analysis. Other positive aspects of the process, is to have a single reaction, but the 
fermentation time is high, approximately 10 hours. 
However, the procedure describes the purification method with little accuracy, because 
according to the recipe only a centrifugation is needed because the active principle remains on 
the surface of the fluid. Therefore, the purification system gives rise to doubts because all the 
processes described above, they require an adsorption step, either by activated carbon and / or 
by chromatography. In addition, it is not mentioned how to eliminate the different impurities 
present in the form of ions that remain in the solution, such as chlorine or metal ions, at no time 
refers to the addition of salts to precipitate that ions present. 
It would be interesting to know the separation of the catalysts from the culture medium, 
because being metallic they can cause a greater impact to the medium, specifically Zinc, which 
is heavy metal. Another aspect related to the recycling of products, is to know the feasibility of 
reusing the culture in more occasions, because the patent does not mention at any time the 
possibility of reusing it, unlike the patent No. 6,057,301 that can be recycled up to three times. 
Finally, regarding the overlap in the equipment, one solution would be to carry out the 
fermentation at the same time as the purification, because the necessary data are not available 




30 Caubera Moreno, Christian 
 
 
 PATENT CN1944661A 
The synthesis of CDP-Choline is carried out through choline chloride, CMP and phosphates 
with a change in the components that act on the culture, to improve its result and at the same 
time lower costs, because it can be reused. 
In the following table, each of the reagents involved in obtaining citicoline is shown, without 
taking into account other compounds that do not intervene in the reaction, such as sodium 
hydroxide to adjust the pH. 
 





Phospho choline 3 Kg 3,75 359 
CMP 1 Kg 1,25 41 
Glucose 10 Kg 12,5 N/A 
Potassium Hydroxide  2 Kg 2,5 N/A 
Culture  30/3 Kg 12,5 N/A 
Table 4: Results of the process 
The main reason why this process has been chosen, has been the emphasis on the recycling 
of materials (point mentioned in the advantages of the patent), specifically the culture, which it is 
multiplied per 0.33 in the tables, to be used up to three times. In addition to presenting these 
benefits, it gets a better performance than the current one, in the same way as the other 
processes. 
The table does not show results regarding productivity time, cost per gram and yield, this is 
due to the fact that the final amount obtained from sodium citicoline is not available in the recipe. 
The main inconveniences of the process, in addition to not offering any data to the amount of 
citicoline produced, and the scant description of each of the operations, it is the high number of 
operations. In the recipe, a total of fourteen operations are shown, which include columns of active 
carbon and chromatographic absorption, requiring a change in the resin, being the 711 (Cl-). With  
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the experience transmitted in the plant, it can be reasoned that such a quantity of operations or 
an optimisation will be necessary. or a considerable amount of the final product will be lost and 
by company policy, it is desired to eliminate this type of operations. 
Referring to overlap, the process is difficult to be apply, having 14 operations, and the only 
stage that is discussed is 6 hours. The process, even in the most favourable circumstance, that 
the reaction time is the slowest stage and a large number of equipment is available to perform 
this operation, will continue to have a lower productivity time for two reasons: the number of moles 
per litter is inferior to the process CN200810019854 having as reference the same yield, 
consequently the amount of API will be lower; and this process needs a culture of 24 four  
 PROCESS COMPARISON 
Once the data have been obtained, the patent that shows the most advantages to be applied 
in the plant will be selected. It is important to note that each of the processes has an improvement 
over the currently used, either substantially increasing the performance, productivity time and cost 
per gram. Therefore, these data corroborate the need to make a change in the process. 
The WO2013 has been selected for the following reasons: 
First, the 2013 patent obtains a longer productivity time than the other processes. As a result, 
the company could reduce campaign time or use smaller equipment, such as reactors of 1.6 and 
/ or 2 cubic meters, reactors that are currently used to manufacture other APIs, or use the 
equipment for the manufacture of paracetamol, with volumes between 10 to 15 cubic meters for 
the reaction. 
Secondly, the possibility of manufacturing citicoline from this process offers to abandon 
operations of high cost and in which a high amount of citicoline is lost, such as the 
chromatographic column. In addition to eliminating these operations, a product with high purity is 
achieved, according to the 99% recipe analysed by HPLC (high performance liquid 
chromatography). However, with regard to equipment, this patent requires a greater number and 
different, such as frozen to separate substances. In spite of this, the balance is favourable to apply 
it because the different operations are common in the pharmaceutical industry, and in the case of 
the others, another column of chromatography (in this case chlorine) or microfiltration must be 
applied. 
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Another relevant aspect for having selected WO2013 is the description of the patent, that is, 
this recipe contains some examples and a more concise explanation. Inside the patent, the use 
of each reagent (along with its quantities) and the operations applied to obtain the final product 
are explained in detail. However, the CN1944661A patent specifies the reactants at a qualitative 
level, but not the quantities required, and for the patent CN200810019854 the purification of the 
product is not precisely detailed. Therefore, more accurate data implies more reliable results in 
its subsequent simulation using the ASPEN Batch process developer. 
It is important to point out that the objective is to perform the basic engineering to obtain 
approximate data that confirm a change in the manufacturing method, therefore, it will not be 
possible to quantify some aspects of the process, such as the recycling of substances, future 
recirculation, etc. On the other hand, apart from the environmental issue, the morpholidate salt of 
Oxalic Acid had been identified as an inconvenience. Despite not being in the recipe, this reaction 
will need to be taken into account throughout the process, an alternative could be to place it in 
series during the fastest stage. 
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5. PROCESS SIMULATION 
Once the selection has been made, the two processes will be simulated in order to assess 
and compare the impact of the new manufacturing method for Ceuber. Given the short information 
provided by the recipe, it is necessary get numbers that best approximate the reality. 
Consequently, the data from plant will be applied, unless it is clearly indicated in the recipes from 
patents. 
In the following table is shown the different operations. The common stages, they will have 
the same operating time, an example of this is “transfer”. 
 
Operation  Ceuber process  New process Time (min) 
Transfer     10 
Mix     15 
Filter     15 
Crystallisation      125 
Charge     5 
Dry     40 
Carbon Column (overall)     200 
Concentrate     40 
Column chromatography     300 
Fermentation      231 
Chemical synthesis      300-420 
Cool     25 
Precipitation reaction     120-240 
Table 5: Changes applied in equipment 
 
Another operation that appears in both process, is “filter”. One Characteristics of the filter, is 
the amount of liquid that the solid retains. Thus, the moisture will retain the 5% of the liquid, in 
every simulation. 
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In the next paragraphs, it will be simulated until the citicoline obtention, not arriving until its 
sodium salt, because patent US 6,057,301 is capable to be applied in both forms. 
It will be focus mainly in the stages that gets the most influence in batch, the reaction for its 
transformation and being the slowest stage, and the purifications, because of the losses in these 
stages are significant. On the other hand, other equipment will be studied in case of being applied 
the process in plant.  
 CURRENT PROCESS 
The simulation of the 3,684,652 process is intended to be as similar as possible to reality, for 
this reason it will be studied under the same conditions developed in plantt. However, it is 
necessary to know the simplifications and / or approximations used in Aspen: 
The actual process obtains a yield of 50% in the different stages of purification, this is due to 
the solution obtained from the fermenter, it passes up to three times through the chromatography 
column, this leads to have a longer operation time. Therefore, in Aspen it will be shown as a single 
process, but the operating time and performance will be real. 
The volume of occupation, will be the maximum that can support the fermenter, being of 95%. 
The reason for applying this critical condition is to study if the new process with an occupation of 
90% gets the same scope. 
The initial reaction has all the components in solid phase; One of these components are the 
cells. However, the cells appear as a solid acetone, to simplify calculations, and dextrose as 
sugar. 
The different stages of purification, aim to show the losses in citicoline not in other 
compounds. Consequently, the final purity of the API can be different from reality. 
Finally, to compare each one of the simulations, it will be done by the number of Batches 
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5.1.1. Process simulation 
In order to facilitate the compression of the process and look the equipment, the layout 
obtained by the simulation is attached. The image does not represent the original plant layout. 
However, in basic engineering, it does not affect the results that are required.  
In the next pages it is add the Aspen recipe, it could be seen, the differences between the 
example from patent and the next.  
  
1. Charge Fermenter F-10000 with 4749,93 liter of Cultivo. 
2 Mix the contents of unit Fermenter F-10000. The mixing time is 30 min. Continuously add 
4749,93 liter of WATER. 
3. Ferment in unit Fermenter F-10000. The yield of CDP-CHOLINE in the Liquid phase is 
0,028133605  (General Range: +/- 4 Percent.), of CHOLINE CHLORIDE in the Solid phase is 
0,10774572, of DEXTROSE in the Solid phase is 0,055668622, of ACETONE in the Solid phase 
is 0,598587334  (General Range: +/- 4 Percent.), of MAGNESIUM-SULFATE in the Solid phase 
is 0,01652101, of POTASSIUM DIHYDROGEN PHOSPHATE in the Solid phase is 0,075422004, 
of DIPOTASSIUM-PHOSPHATE in the Solid phase is 0,10774572 and of CYTIDINE-5' 
MONOPHOSPHATE in the Solid phase is 0,010175985  (General Range: +/- 4 Percent.). The 
fermentation time is 231 min. The final temperature is 30 C. The heat of reaction is 15000 kJ/kg 
of component CDP-CHOLINE in Liquid transformed. Use 100 C Hot Water on the Entire Jacket. 
 
Figure 13: Process Layout 
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4. Transfer contents of unit Fermenter F-10000 to ST-D. This is the key step output. The 
transfer time is 10 min. 
5. Filter the batch from unit ST-D in filter FI-400. The transfer time of the slurry is 30 min. 
Transfer 50% of the batch to the filter. The mother liquor, named Solución, is sent to Fuji Paudal 
VMixer VM-2000. Transfer the mother liquor via Tubing. The cake contains 91% of CHOLINE 
CHLORIDE in the solid phase, 96% of POTASSIUM DIHYDROGEN PHOSPHATE in the solid 
phase, 100% of MAGNESIUM-SULFATE in the solid phase, 99% of DIPOTASSIUM-
PHOSPHATE in the solid phase, 89% of DEXTROSE in the solid phase, 75% of CYTIDINE-5' 
MONOPHOSPHATE in the solid phase and 99% of ACETONE in the solid phase. The moisture 
content in the final cake is 5%. 
6. Mix the contents of unit Fuji Paudal VMixer VM-2000. The mixing time is 15 min. Maintain 
the temperature of the batch at 25 C. The agitator is Spinbar. The rotation speed of the agitator 
is 200 Rev/min. Continuously add 952,42 liter of Hydroxide solution. 
7. Transfer contents of unit Fuji Paudal VMixer VM-2000 to ST-B. This is the key step output. 
The transfer time is 10 min. 
8. Clean unit FI-400. Cleaning time is 20 min. 
9. Filter the batch from unit ST-D in filter FI-400. The transfer time of the slurry is 30 min. 
Transfer 100% of the batch to the filter. The mother liquor, named Solución almacenada, is sent 
to Fuji Paudal VMixer VM-2000. Transfer the mother liquor via Tubing. The filter separates 100% 
of all solids. The moisture content in the final cake is 5%. 
10. Mix the contents of unit Fuji Paudal VMixer VM-2000. The mixing time is 15 min. Maintain 
the temperature of the batch at 25 C. Continuously add 952,42 liter of Hydroxide solution. 
11. Transfer contents of unit Fuji Paudal VMixer VM-2000 to ST-D. This is the key step output. 
The transfer time is 10 min. 
12. Transfer contents of unit ST-B to ST-D. This is the key step output. The transfer time is 
10 min.3. Separation (chromatography) 
13. Load the column Chromatography 100. Use 100% of the material in ST-D. The transfer 
time is 60 min. The resin retains 92% of CDP-CHOLINE. 
14. Wash the column Chromatography 100. Use 3809,7 liter of WATER. The transfer time is 
30 min. The column retains 30 liter of the solution. The solution removes 11,429% of the column  
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resin contents. Spent Wash Stream: The spent wash is sent to ST-D. Transfer the spent wash via 
Tubing. 
15. Elute the column Chromatography 100 with 6666,96 liter of FORMIC-ACID. The elution 
time is 68 min. Collect 6190,75 liter at 476,21 liter into the elution. The cut is sent to ST-C. The 
solvent removes 87% of CDP-CHOLINE. Unspecified components are sent to waste. 
16. Load the column Column carbon Generic. Use 100% of the material in ST-C. The transfer 
time is 50 min. The resin retains 98% of CDP-CHOLINE. 
17. Elute the column Column carbon Generic with 285,72 liter of WATER. The elution time is 
49 min. Collect 238,11 kg at 28,572 kg into the elution. The cut is sent to AT Crystallizer 10 cubic 
meters. The solvent removes 86% of CDP-CHOLINE. 
18. Crystallize the batch in unit AT Crystallizer 10 cubic meters. The following components 
are separated in the crystal phase: 91% of CDP-CHOLINE. The crystallization time is 117 min. 
Continuously add 2857,27 liter of WATER. 
19. Transfer contents of unit AT Crystallizer 10 cubic meters to Dryer 5 cubic meters. Transfer 
100% of vessel contents. The transfer time is 10 min. 
20. Dry the batch in unit Dryer 5 cubic meters. The drying time is 2 h. The drying temperature 
is 50 C. The moisture content in the final cake is 5%. 
21. Transfer contents of unit Dryer 5 cubic meters to SS tank. This is the key step output. The 
transfer time is 10 min. 
5.1.2. Results discussion 
The results obtained from ASPEN, demonstrates the two main inconvenience in that process, 
the fermenter and the purification. The biological reactor, is the step that requires the most time 
during the manufacture, therefore is the controlling stage. It implies, that an increase of 
production, pass through a change in the volume of the reactor, being more than 10.000 litters. 
In addition, the yield of the reaction is higher than the recipe, because it is also optimized, 
obtaining 133 kg of crude citicoline, and the CMP it’s consumed the 77%. If the operation gets 
the same yield as the recipe, it will get 119.7 Kg as crude citicoline, in the same volume, the 95% 
of the fermenter. 
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In the campaign results, the data obtained are in 72 batch, obtaining 69kg/Batch and the time 
necessary to get this scope is 19.9 days. This process it will be repeated until 6 times per year, 
to obtain almost 30.000 Kg 
This Figure 14 is the occupation in each batch, and the reactor, is the equipment that has the 
highest percentage of volume, excepted both columns, because during the process, the average 
components that flows through that, is higher than its capacity. Moreover, in the average cycle 
time, the reactor is the equipment that consumes the most of time, it implies its bottleneck 
condition [Figure 15] 
The ressults obtained in ASPEN demonstrate that a improvement in the process should pass 
through either reducing the reaction time or mprove the volum productivity and get beter results 
in the purification stages. 
In this plant, the number of API that requires a bioreactor of this volume is minimum, moreover 
it is the most manufacture process in this plant, before the paracetamol (it use a chemical reactor). 
Therefore, to increase this volume has low viability, and the existence of the generic drug, implies 
that Cemicina will not increase its demand considerably. Then, the corporative necessity is get 
better productivity to reduce costs. 
Figure 14. Size utilization 




In the chromatography column, despite the citicoline lost in this stage, at the moment is not 
possible to get better yield, because as it is said before, it has been optimized, increasing the 
yield up to 50% in this stage. The only alternative is either get another cycle, but it could provoke 
that the slowest stage will become the purification or obtain another patent to purification the 
citicoline, such as the KR101311571B1. 
About the results obtained in the campaign, the low quantity achieved in each batch requires 
an optimisation in the process, concretely in the overlap. For this reason, it is used some tanks to 
avoid that an inexpensive stage, it can produce a higher time per batch. Next images, show the 




Figure 15. Cycle time. 
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 PROCESS WO2013/128393 
In order to obtain coherent information to make future adjustments, the results should be the 
most similar with reality, then an escalade will be carried out to get it. The scale consists of three 
parts, the recipe (text offered by the patent), after that, the process is developed in a pilot plant to 
adjust, and finally develop it in plant. In the annex is possible find each of the recipes. 
The simulation of the process 128393 in Aspen, it will be carried out in two situations, an 
unfavourable condition compared with a more favourable (modifying equipment, yield reaction 
and yield in purifications), with the aim to quantify the improvements and study if in both conditions 
is obtained the scope. However, the reaction times will be the same, because it is indicated in the 
patent recipe. 
5.2.1. Unfavourable situation 
The process will be developed in the most disadvantageous conditions possible, always within 
the margins offered by the patent, or extrapolated from the patents previously exposed (only the 
performance of the reaction). These conditions are the following: 
Performance of the reaction: In both syntheses, the limiting reagent will have a conversion 
of only 75% CMP. However, the yield obtained in the recipe, it is unreliable because the CMP 
represents in weight approximately the 75%, then if is add 100g of CMP, it is not possible get 
2625g of citicoline.  
Equipment of the process: The equipment will not undergo any modification, except in the 
reactor, this will affect the equipment to work in lower capacities than the designed. However, this 
process is carried out by chemical synthesis, so it will use a reactor available during the Cemicina 
campaigns. This reactor has a volume of 1600 liters, but it will be used in two possibilities, the 
90% of volume, using 900 liters, to compare with the favourable situation and evaluating the effect 
of the losses in reaction yield and purification, because the favourable situation use a reactor of 
1 cubic meter in the second reaction. 
Stages of purification: One of the characteristics that the citicoline production is so 
expensive; it is its low efficiency in the purification stages. The following simulation will show a 
productivity that is far from the one described in the example. 
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5.2.1.1. Process simulation 
In the Annex of the project, it could be founded the process in the different stages of the 
scalation, the recipe (laboratory), pilot plant and the generic plant. To simulate the described 
condition, it has been modified the capacity of adsorption in the carbon column, and the 
crystallization (the precipitation reaction) the amount of citicoline no precipitated, is higher.  
The elaboration of this simulation it has been done at the same time that the real condition, 
for this reason, it will be studied in two ways the process in ASPEN, to get results with the same 
quantity of raw materials in each situation (the unfavourable and the real one) and finally 
comparing the influence of the variations in yield (reactions and precipitation) and finally, using 
the 90% of the reactor, as is has been stipulated. 
To get the results, it has been scaling every stage and finally, to replace the equipment from 
the current process. During the replacement, it has been appearing some problems about the 
volume, because the amount of liquid, is considerably minor than the current, hence, some 
operations are not developed in the design condition, such as the crystallizer.  
5.2.1.2. Results discussion 
The application of this method in Aspen, demonstrates the high capacity of this invention, 
even though, having the worst situation described in the patent. In this condition, using a 26.91 
day, the campaign objective is obtained in 64 batch (79 kg/batch). It shows that is not possible 
obtain the scope, due to reactor time. 
Figure 17 indicates the low occupation in each stage, having a reduce operation volume, but 
increasing considerably the obtention of crude citicoline, if it is compared with the current one. 
However, the utilization of only one reactor, difficult the optimization of the process, because its 
reactor requires elevate time of operation and the reactant volume should be moved to different 
stages, such as the cooler, staying the reactor empty and losing time to manufacture citicoline. 
The differences between figure 18 and figure 19 is adding the time when reactor is empty, it shows 
the inconvence in use a single reactor. 
 
 













































Figure 17. Size utilization. 
Figure 18. Cycle time overwiew. 
Figure 19: Cycle time overwiew evaluating when reactor is empty 
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Purifications stages, gets better productivity removing chromatography column. In the first 
process, the losses caused by the different stages of purification represents the 47%, getting as 
a product 133.62Kg of crude citicoline in front of 69.72Kg as purified product. In this case, the 
losses represent 9.56%.  
Both increases in productivity, shows the problems can be solved through changing the 
process to manufacture this API. However, a reduction of time in the imitating stage, it will offer 
to Ceuber gets the same scope with less 
time, given that the citicoline obtention is 
developed in two reaction, a possibility is 
install other reactor. Finally, the column 
needs this large number of hours [Figure 21] 
because is directly related with the reactor, 
because it is in use but no working, as it shown 
in Figure 20. 
 
On the other hand, applying the changes to get better yield in purification and reaction it will 
increase substantially the productivity, but is not the most significative point. In case to apply these 
improvements, the citicoline manufactured is 112.Kg per Batch, in this situation, the process is 
capable to obtain the scope in the time that is determined by campaign. Next paragraphs make  














Figure 20. Time used by column. 
Figure 21. Cycle time Overwiew 
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Figure 22. Shedule process. 
 
evident that another reactor should be install to get better productivity and improve the 





5.2.2. Real situation 
In this case, the process will be carried out with an optimization of the equipment, in order to 
obtain a better productivity time, the reactions will be a yield of 85%, unlike 75%. Finally, in the 
different purification stages (carbon column and precipitation reaction), the losses in the active 
principle will be lower. 
Another consideration to realize the simulation, it is the no preoccupation to use a large 
number of equipment, for instance the tanks. The reason to manage this quantity of tanks, it is for 
do no create bottleneck in operations that the cost is not elevated. Moreover, the tanks used, 
there are available in plant (the tanks with high volume) and simulating news, with less volume, 
for example the “Tank Set”. 
In the following table, it shows some changes applied in the process: 
 
Equipment  Worst situation Real situation 
Reactor 
  
De Dietrich 1600 liters 
  
De Dietrich 1000 liters 
DIN Reactor 800 liters 
Filter 
  
Fi-400 (4000 liters) 
  
Belt Filter (100 liters) 
Filter P100 (100 liters) 
Crystallizer  AT crystallizer 10000 liters AT crystallizer 2000 liters 
 Table 6: Changues applied 
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5.2.2.1. Process simulation 
The method to realize this simulation, it is using the previous one and changing the different 
equipment in order to get better results but using the same amount of raw materials, to observe 
the influence in productivity time and in the same time, how affect that in campaign time. The prior 
results, demonstrates that the reactor is the operation that needs more time, being two reactions 
in the same recipe, taking into account that the prior has a reaction volume of 1.6 cubic meter, it 
will be applied two reactors (one of 1000 liters and another one of 800 liters), these changes 
implies a reduction of more than three hours in each batch.  
However, after these changes, it appears problems in tanks and filter, becoming these 
equipment that needs almost time, to face with this problem, it has been applied some tanks and 
clean two times the filter per batch. 
 Finally, every equipment 
that is used in this simulation, are 
predefined in ASPEN (with the 
exception of the first reactor), it 
could imply that exists equipment 
that suits better this improvement 
and some equipment are reused, 
such as the carbon column. 
This ASPEN recipe, it could be 
founded in the annex with all details.  
5.2.2.2. Results discussion 
Table 7 shows the number of products in the last stage in that simulation, the changes applied 
in the reaction yield and the different stages of purification (the adsorption column and the 
precipitation), it allows for getting an increase of 19kg in each batch, using the same quantity of 
raw materials and the same reaction volume, respect the simulation described above. Obtaining 
80Kg in each batch, the number of batches it will decrease, and finally, the campaign time.  
 
Table 7. Citicoline obtained 
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To get the same scope as the first simulation (current process) it is necessary to apply 68 
batches, in conditions of overlapping, then the campaign time will decrease considerably, being 
22721 min, or 15.778 days. As it is said in the simulation, putting a second reactor increase 
considerably the productivity reducing the batch time. Now, the slowest stage continues being the 
reaction, but reducing its time that occurs in 5 hours and 40 minutes (charge the recipient, the 
reaction and transfer). In the requirements, it has been pointed out that the reaction volume is the 
90% to get the scope in a less severe conditions to manufacture, because the fermenter it has 
been designate to be operate with a capacity of 90% not the 95% as it has been simulated, that 
is its maximum capacity. Figure 23 shows the different capacity in each operation and Figure 24 
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Figure 23. Size utilization 
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This renovation offers to the company two ways to carry out, either reducing the campaign time 
or use equipment with less volume: 
The ability to manage better the campaign time, it allows the company to ensure its production 
time in case of an important fail. No having results about the necessities of cleanliness in this new 
process, it could imply a longer time to do this operation, and it affects the process time. Finally, 
a reduce number of cycles, it provokes a longer life in the equipment. 
On the other hand, the reduction in the equipment volume, implies a reduction in the 
























Figure 24. Cycle time overwiew. 
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Current 69 72 19,9 days 4968 95 
Unfavourable 






days 5032 90 
Table 8: Summary of results 
* unfavourable condition (yield 75% in reactions) is not developed because no gets the scope. 
In order to compare which process has the best results, and finally, make a decision about 
the viability to Ceuber to change the process, it will be done through the next results: Productivity 
time and productivity time volume, as the prior section, but using productivity time column 
because the three reactors have got different volume. For this reason, it has not been into a 
consideration the influence of the other recipient volumes, because the stage that modifies these 
results, are the reactors. It is important to point out that the reactor volume for the “real” will be 
the biggest one, with 1000 liters. 
The productivity time volume (PTV) is evaluated as follows: 
 
Then, the results obtained in each process, are the next. 
Process PT (Kg/days) PTV (Kg/liter*day) 
Current 249.65 2.49*10-2 
Unfavourable condition 242.26 0.15 
Favourable condition 318.92 0.318 
Table 9: Results obtained 
𝑃𝑇𝑉 =
𝑀𝑎𝑠𝑠 𝑜𝑓 𝑝𝑢𝑟𝑒 𝑐𝑖𝑡𝑖𝑐𝑜𝑙𝑖𝑛𝑒
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The results, demonstrates the high viability to study this process experimentally and analyse 
its future development in plant. Obtaining an increase of 1.5 in times PT and 13 times PVT, it 
indicates that the corporative objective is obtained, because exists a process that gets greats 
results with low volume in the reactor and eliminating the chromatography column.  
The two different simulations, regardless the modifications in the different reactions, indicates 
that there are two ways to apply this process: Either through overlapping the two different reactors, 
or using only one: 
The management of one reactor, it provides Ceuber some positive aspects. The space of one 
reactor, its less than two, such as its security distance between others, and in a plant, the saving 
space is important. Increasing this reactor volume, it also provokes that the cycles per campaign 
is less than the other option. The control of one reactor, it could be easier than two and in the 
same time, it avoids to change less the products between different equipment and this possibility, 
that obtains the requirements to be applied, even though in bad conditions about yield, it gives 
the possibility to reuse its chemical reactor. 
The most important of this point is the possibility to develop the process with the equipment 
available in plant, as a condition of the requirements. This application has some alternatives, but 
everyone has an inconvenience, such as the low occupancy in the different stages, being a waste 
in energy, or the other situation is applicate the paracetamol reactors, but these will create a great 
problem to storage the API. 
On the other hand, the PTV in the situation that the rector is overlapped, it is much higher 
than the another one, even though using the same productivity in each stage. Other reason to 
discard this option, is the chemical reaction, because it consists in two parts, having in the middle 
a separation that implies freeze the solution, then, the solution must be moved from the reactor. 
Moreover, the option to use two reactors, it adequate better in the current process, because the 
reaction needs more or less the same time, easing the application in plant.    
It concludes that, with the exception of the low space available in plant, taking into account 
that Ceuber will not move the fermenter, because it is used in other APIs; the best solution is 
apply two reactors, as it has been simulated in ASPEN, using a 90% of occupation. Despite having 
been simulated this option, the company could apply modifications in the reactors volume to  
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obtain the same scope in higher time and less volume, ever depending in the available necessities 
of the company, such as space, workforce, etc and affecting as little as possible, in the 
manufacture of other APIs. The application of this process in this condition, ensure its obligation 
in case of adverse event, such as an equipment fail and an unexpected demand. 
However, despite having a large number of benefits aspects, it should be taking into a 
consideration the next points: 
Firstly, a change in a pharmaceutical process it ought to be notice to EMA, and finally needs 
to get the approbation of this agency. The no obtention of this permission because of no approves 
the GMP, prevent the commercialisation of Cemicina. Then, if it is decided to change the process, 
it should be ensuring that this process comply and the no possibility to reduce the quality of this 
API. 
The aspects that are related with products are the next: there are not suppliers that offer the 
morpholidiate salt of oxalic acid, provoking the necessity to manufacture this product. Despite 
offering other options in the description of this patent, the utilization of other component, it could 
affect in the precipitate reaction, getting worst results. Therefore, in pilot plant, it should be studied 
the different possibilities in order to get the best results and in case of manufacturing this salt, to 
analyse which option is the best for the company: either manufacture this compound in its fine 
chemical plant, to increase the batch time or adding a new stage during the overlap. Other 
consideration about these compounds, are this elevate hazard to human, then, it should be 
studied the possibility of traces, such as HCL, oxalates, to avoid its dangerous effects. 
  The reduction of volume in the different equipment, provoke the reduction in energy and 
its environmental impact. However, this new process, it should be analysed with detainment to 
not lose the ISO 14001. 
 To conclude, the results obtained in ASPEN studying the basic engineering, that are 
capable to demonstrate the high viability of the process. Although, this process should be 
evaluated experimentally in order to evaluate its development, because of these numbers are not 


































-The bibliographic search demonstrates the advances made in the production of citicoline; 
corroborating the need to analyse the possibility to obtain a new process. 
 
-Throughout the project, it is confirmed that the WO2013128393 patent is the one that is 
adapted to improve the corporate requirements, eliminating high cost operations. 
 
-In the simulation of the two processes using Aspen Batch process developer, results are 
obtained exceeding expectations, increasing PTV up to 20 times. 
 
-The maximum productivity, under the conditions established by the company, is obtained 
through the application of the patent WO2013128393 overlapping two reactors. 
 
-It is not possible to say categorically that the application of this process is the best for the 
company. However, the need to be studied more thoroughly is demonstrated in order to 
obtain data that does not reach basic engineering. 
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APPENDIX 1: STUDIED PATENTS 
 
Patent CN104031105A 
Method for preparing citicoline sodium 
Abstract 
A method of preparing the citicoline sodium, oxalic acid was added to the aqueous solution 
of calcium phosphate, choline chloride, and the precipitate was removed after the water, in a solid 




Process for preparing citicoline sodium 
Abstract 
The present invention is process of preparing citicoline sodium. The preparation process 
includes the biotransformation of material including 5'-cytidylate, phosphorylcholine, potassium 
hydroxide and glucose with culture as the biocatalyst; extraction and separation with active carbon 
as the adsorbing carrier, Cl- type ion exchange resin as the separating carrier and re-compounded 
water-alcohol mixture as the analyzing reagent; and product purification with alcohol solvent as 
the crystallizing solvent. Compared with available technology, the present invention has the 
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Patent CN 105732752A 
Citicoline and synthetic method thereof 
Abstract 
The invention discloses citicoline and a synthetic method thereof.The synthetic method 
includes subjecting cheap and easily available cytidine, serving as a raw material, and 
dichlorophosphoryl morpholine to condensation at a 5' position highly selectively so as to obtain 
5'-phosphorylmorpholinylcytidine; subjecting the 5'-phosphorylmorpholinylcytidine and 
phosphocholine chloride calcium to condensation in solvents so as to obtain the citicoline.Total 
yield is up to 58% only by the two steps.The synthetic method is cheap in and easily avai lable to 
raw materials, expensive cytidine monophosphate is unused, operation steps are simplified, and 
reaction scale can be expanded to synthesize 500 g of citicoline.The synthetic method has a 
potential application prospect by providing a novel citicoline synthetic route. 
 
Patent CN 103849666 A 
Method for catalytically producing citicoline sodium with immobilized enzyme  
Abstract 
The invention provides a method for catalytically producing citicoline sodium with an 
immobilized enzyme. The method comprises the following steps: by utilizing engineered 
escherichia coli of a molecularly cloned cytidine phosphotransferase gene for fermentation, 
preparing cytidine phosphotransferase, and preparing cytidine phosphotransferase liquid through 
purification; immobilizing cytidine phosphotransferase; by using phosphorylcholine and cytidine 
disodium triphosphate as raw materials, catalytically generating citicoline with immobilized 
cytidine phosphotransferase. The method is simple in production process, short in production 
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Patent CN 102586383  
Process for preparing cytidine diphosphate choline  
Abstract 
The invention relates to a process for preparing cytidine diphosphate choline. According to 
the method, denovo synthesis of pyrimidine is utilized as a basic reaction and choline materials 
are subjected to a reaction at the reaction temperature ranging from 20 DEG C to 38 DEG C for 
10 to 72 hours with pH controlled at 5 to 7.5 in the presence of culture solution of microorganism 
A or further in the presence of culture solution of microorganism B or treatment so as to 
accumulatively produce cytidine diphosphate choline. Simple starting materials of carbon and 
nitrogen sources are utilized, in culture solution containing the choline materials, precursor of the 
cytidine diphosphate choline, namely cytidine monophosphate is synthesized by means of 
metabolic process, and cytidine diphosphate choline is cumulatively produced in the reaction 
solution. According to the method, expensive cytidine monophosphate or the precursor materials 
are avoided so that the preparing cost of the cytidine diphosphate choline is greatly reduced. 
 
Patent CN 102199643 A 
Preparation method of citicoline  
Abstracte 
The invention discloses a preparation method of citicoline. The method comprises the 
following steps: the culture of a single gene engineering bacterium or the treatment material of 
the culture is used as enzyme source to catalyze the reaction of a substrate comprising 
ammonium chloride, orotic acid and phosphocholine and ensure that citicoline is generated and 
accumulated in the reaction solution, and citicoline is extracted from the reaction solution. The 
invention has the following beneficial effects: (1) the single microorganism is utilized to catalyze 
the reaction, reaction conditions are easy to control; (2) the cost of the substrate is lower so that 
the production cost of citicoline is lower; and (3) the reaction is fast and the conversion rate is 
higher. The method can be widely used in the preparation of citicoline. 
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Patent CN 101265453 A 
Screening and application of beer microzyme containing CMP kinase and CDP kinase 
Abstract 
The invention relates to a method for screening Saccharomyces cerevisiae with high-activity 
CMP kinase and CDP kinase, and the use of the Saccharomyces cerevisiae in the production of 
cytidine triphosphate, and belongs to the technology field of biological engineering. The 
Saccharomyces cerevisiae strains is preserved in the China General Microbiological Culture 
Collection Center (CGMCC) with accession number of CGMCC NO.2448. The Saccharomyces 
cerevisiae strains with high-activity CMP kinase and CDP kinase are screened by means of 
nitrosoguanidine (NTG) mutagenesis. In the production of the cytidine triphosphate, the 
Saccharomyces cerevisiae strains are used to be prepared into immobilized cells of various grain 
diameters with carrageenan as carriers by different controlled stirring speeds realized through 
embedding. Compared with manual cutting, the screening method of the invention has the 
advantages of small cell leakage, regular grains with high strength, low labor intensity, simple 
grain-producing procedure, no complicated equipment and instrument, and is suitable for 
industrialized production. Furthermore, bean oil used in the invention is safe and nontoxic solvent, 
suitable for various requirements and easy to recycle. 
 
Patent CN201410247176 
Method for preparing citicoline sodium by utilizing oxalyl chloride 
Abstract 
The invention discloses a method for preparing citicoline sodium by utilizing oxalyl chloride. 
The method is characterized by comprising the following steps of: by taking choline chloride 
calcium phosphate (P-choline) as a raw material, dissolving in organic amine not containing 
reactive hydrogen, adding oxalyl chloride for reacting for 0.5-2 hours after adding benzene for 









Overexpressed phosphorylcholine cytidine transferase saccharomyces cerevisia genetically 
engineered bacteria as well as construction method and application thereof. 
Abstract 
The invention relates to overexpressed phosphorylcholine cytidine transferase 
saccharomyces cerevisia genetically engineered bacteria as well as a construction method and 
application thereof. The construction method comprises the steps of cloning saccharomyces 
cerevisia sourced gene cct capable of encoding phosphorylcholine cytidine transferase to a 
pYES2.0-Kanmx carrier so as to construct recombinant plasmid pYES2.0-Kanmx-cct, and 
transferring the recombinant plasmid pYES2.0-Kanmx-cct into S.cerevisiae HG, so as to obtain 
the saccharomyces cerevisia genetically engineered bacteria. The yield of a solid matter of the 
strain to fermentable sugar is 50%-56%, the strain can be used for manufacturing a citicoline 
product from 5'-cytidine monophosphate and phosphorylcholine through bioconversion, and after 
the strain reacts for 7 hours, the molar conversion ratio reaches up to 73%. The yield of the strain 
in a fermentation system for producing and culturing the strain is high. When applied to the 
production of citicoline, the strain has the advantages of low cost and manufacturing energy 
consumption, short reaction period and the like. 
 
Patent CN101906126B 
Method for separating purified cytidine diphosphate choline by hydrophobic chromatography 
Abstract 
The invention discloses a method for separating purified cytidine diphosphate choline by 
hydrophobic chromatography. The method comprises the following steps of: (1), performing  
enzyme inactivation, centrifugation and ultra-filtration of a cytidine diphosphate choline conversion 
liquid; (2), after adjusting the pH of the pre-processed cytidine diphosphate choline conversion 
liquid to between 2.0 and 14.0, adding an inorganic salt to prepare column-loading liquid which 
contains 0.01 to 5mol/L of inorganic salt and 0.1 to 40g/L of cytidine diphosphate choline with the 
cytidine diphosphate choline conversion liquid, absorbing the column-loading liquid with a  
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hydrophobic chromatography resin and eluting with pure water of which the pH value is 2.0 to 
14.0; and (3), nano-filtering, desalinating and concentrating the eluate, and obtaining the cytidine 
diphosphate choline through crystallization. In the method, the separation process is simple; 
through regeneration, the resin after elution can be repeatedly used; the separation cost is low; 
the product is easily crystallized; and the CDP-choline product with high purity and high yield can 
be obtained. 
 
US patent 3.684.652 
Method for preparing cytidine diphosphate choline 
Abstract 
Cytidine diphosphate choline is prepared by cutlturing an aqueous reaction liquor containing 
(a) at least one of the class consisting of choline or phosphoryl choline; (b) at least one of the 
class consisting of cytidine, cytindine 5''monophosphate, cytidine-5''-diphosphate or cytidine-5''-
triphosphate; (c) enzyme systems of bacteria, cultures or molds; (d) phosphate ion and (e) at least 
one of the class consisting of magnesium ion and manganese ion and recovering cytidine 
diphosphate choline from said culturing liquor 
 
KR101311571B1 
Method for purification of cytidinediphosphoric choline 
Abstract 
The present invention, pH is 0.5 or greater than 5.0 of cytidine is by phosphoric acid choline 
solution in contact with H-type strong acid cation exchange resin, the cytidine water or ion 
concentration of 0.1 with phosphoric acid choline adsorbed onto the resin containing the nucleic 
acid related substances by elution with an aqueous solution of below mol / ℓ, the cytidine and 
cytidine characterized in that the purified phosphoric acid choline is an object of the invention to 









Purification of cytidine-5'-diphosphate choline 
Abstract 
PURPOSE: To purify the titled compound economically on an industrial scale, by contacting 
an aqueous solution of crude cytidine-5'-diphosphate choline with a strongly acidic ion exchange 
resin and a weakly basis ion exchange resin, thereby specifically adsorbing and removing the 
impurity components from the solution. 
CONSTITUTION: An aqueous solution of a chemically synthesized crude cytidine-5'-
diphosphate choline (abbreviated as CDP-choline) is made to contact with a strongly acidic ion 
exchange resin (e.g. a resin produced by sulfonating a crosslinked polystyrene) and a weakly 
basic ion exchange resin, preferably by using a column, and usually, the treated aqueous solution 
is concentrated. The CDP-choline can be crystallized by purifying the concentrated solution with 
an alcohol. The CDP-choline solution used as the raw material has a CDP-choline concentration 
of preferably 3W10wt%. 
 
Patent WO2013128393A1 
A process for preparing pure citicoline (cdp-choline) 
Abstract 
Disclosed herein is a process for preparing highly pure Citicoline (CDP-Choline) or sodium 
salt of Citicoline with the aid of dicarboxylic acid or its salts. The process of the present invention 
results in Citicoline with a purity of more than 99% measured by HPLC. 
 
Patent CN102010454B 
Citicoline sodium compound and new method thereof 
Abstract  
The present invention provides a citicoline sodium compound and new method thereof, 
wherein purification is performed via active carbon adsorption, acidification reaction and preparing 
68 Caubera Moreno, Christian 
chromatographic column, finally a citicoline sodium compound with high purity is obtained; the 
shortage of low raw material purity in the prior production is recovered, simultaneously the quality 
of preparation product is improved, and side effects are reduced. Compared with the prior art, the 
method has the advantages of simple and easy technology, low cost, high yield and high product 
purity; the method is suitable for industrial production; and the citicoline sodium prepared by the 
refining method of the present invention is suitable for being used in preparation of neural 
activation agent pharmaceuticals. 
 
US Patent 6.057.301 
Hyperhydrated citicoline, process and use 
Abstract 
A hyperhydrated form of citicoline and its formulations, which exhibits desirable 
characteristics, including crystal formation, moisture resistance, improved storage stability, and 
formulation versatility, is disclosed. Methods of preparing the citicoline hyperhydrate and its use 
in the manufacture of stable pharmaceutical dosage forms are also described. 
 
US Patent 3.687.932 
Crystalline cytidine-5{40 -diphosphate choline monohydrate and production thereof 
Abstract 
Crystalline cytidine-5''-diphosphate choline monohydrate is produced by a. adding a 
hydrophilic organic solvent to an aqueous solution system of cytidine-5''-diphosphate choline in 
the ph range of from about 2 to about 4, or b. keeping cytidine-5''-diphosphate choline standing 
at a relative humidity of not less than about 32 percent and at a temperature in the range of from 
about 17*C to about 70*C for not shorter than about 5 days. 
 
US patent 3666748 
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Cytidine-5''-diphosphate choline and deoxycytidine-5''-diphosphate choline are produced by 
reacting cytidine (or deoxycytidine)-5''monophosphate with a choline phosphoramidate. Choline 
phosphoramidates of the formula WHEREIN R1 and R2 represent hydrogen, a hydrocarbon 
residue having at most seven carbon atoms, or R1 and R2 taken together represent a five- or six-
membered heterocyclic ring are prepared by reacting phosphorylcholine with an amine. 
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Escalade: 1st step: Laboratory process  
Recipe: 
 
1. 1st part  (R1 +C1 +F1) 
1.1. Charge Erlenmeyer Flask, 1000 ml with 137,5 g of CMP MET MORPH DCC. Charge 
Erlenmeyer Flask, 1000 ml with 375 ml of METHANOL. Dissolve 0,1%  of all solids. 
1.2. React in unit Erlenmeyer Flask, 1000 ml via R1. Reaction occurs over 5 h. The final 
temperature of the batch is 55 C. 
1.3. Cool unit Erlenmeyer Flask, 1000 ml to -30 C. The cooling time is 35 min. 
1.4. Filter the batch from unit Erlenmeyer Flask, 1000 ml in filter FILTER FLASK, 1000 ml. The 
transfer time of the slurry is 25 min. Transfer 100% of the batch to the filter. The mother liquor, 
named Solución 1, is sent to Round Bottom Flask, 1000 ml. The filter separates 99% of all solids. 
The moisture content in the final cake is 5%.2.  
2nd part (R2+C2+F2) 
2.1. Transfer contents of unit Round Bottom Flask, 1000 ml to Erlenmeyer Flask, 1000 ml. 
This is the key step output. The transfer time is 10 min. 
2.2. Charge Erlenmeyer Flask, 1000 ml with 200 g of Calcium phosphorylcholine chloride. 
Dissolve 0,01%  of all solids. 
2.3. React in unit Erlenmeyer Flask, 1000 ml via R2. Reaction occurs over 3 h. The final 
temperature of the batch is 50 C. Continuously add 10 ml of HCl-methanol. 
2.4. Cool unit Erlenmeyer Flask, 1000 ml to -30 C. The cooling time is 25 min. Continuously 
add 100 ml of ISOPROPYL-ALCOHOL. 
2.5. Filter the batch from unit Erlenmeyer Flask, 1000 ml in filter FILTER FLASK, 1000 ml. The 
transfer time of the slurry is 30 min. Transfer 100% of the batch to the filter. The mother liquor, 
named Crudo de Citicolina, is sent to Round Bottom Flask, 1000 ml. The filter separates 99,7% 
of all solids. The moisture content in the final cake is 5%. 
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2.6. Transfer contents of unit Round Bottom Flask, 1000 ml to Crystallizing Dish, 1000 ml. The 
transfer time is 10 min.3. 
 Purification 
3.1. Crystallize the batch in unit Crystallizing Dish, 1000 ml. The following components are 
separated in the crystal phase: 99,2% of CITICOLINE, 0,1% of Calcium phosphorylcholine 
chloride and 3% of Morpholidiate cytidine 5-monophosphate. The crystallization time is 125 min. 
Continuously add 69,15 g of Morpholidiate cytidine 5-monophosphate. 
3.2. Load the column Columna cromatográfica. Use 100% of the material in Crystallizing Dish, 
1000 ml. The transfer time is 20 min. The resin retains 98% of CITICOLINE. Displaced Liquid 
Stream: The displaced liquid belongs to category: Organic Waste. 
3.3. Wash the column cromatográfica. Use 10 liter of WATER. The transfer time is 10 min. 
The column retains 2 liter of the solution. The solution removes 89.934% of the column resin 
contents. Spent Wash Stream: The spent wash is sent to Round Bottom Flask. 
3.4. Filter the batch from unit Round Bottom Flask, 1000 ml in filter Filter Flask, 125 ml. The 
transfer time of the slurry is 10 min. The moisture content in the final cake is 5%. 
3.5. Concentrate the batch in unit Filter Flask, 125 ml. The operation time is 40 min. The 
overhead is sent to Round Bottom Flask, 250 ml. Separation is: 99% of CITICOLINE goes to 
Bottoms. Unspecified materials go to Overhead. 
 
Escalade: 2st step: Pilot plant 
Recipe: 
1. 1st part (R1 +C1 +F1) 
1.1. Charge Reactor De Dietrich DIN Reactor AE 63 with 13057,11 g of CMP MET MORPH 
DCC. Charge Reactor De Dietrich DIN Reactor AE 63 with 35610,31 ml of METHANOL. Dissolve 
0,1%  of all solids. 
1.2. React in unit Reactor De Dietrich DIN Reactor AE 63 via R1. Reaction occurs over 5 h. 
The final temperature of the batch is 55 C. 
1.3. Transfer contents of unit Reactor De Dietrich DIN Reactor AE 63 to SS tank 429. 
1.4. Cool unit SS tank 429 to -30 C. The cooling time is 35 min. 
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1.5. Filter the batch from unit SS tank 429 in filter Bag Filter 100. The transfer time of the slurry 
is 25 min. Transfer 100% of the batch to the filter. The mother liquor, named Solución 1, is sent 
to SS tank 429. The filter separates 99% of all solids. The moisture content in the final cake is 
5%.2.  
2nd part (R2+C2+F2) 
2.1. Transfer contents of unit SS tank 429 to Reactor De Dietrich DIN Reactor AE 63. This is 
the key step output. The transfer time is 10 min. 
2.2. Charge Reactor De Dietrich DIN Reactor AE 63 with 18992,16 g of Calcium 
phosphorylcholine chloride. Dissolve 0,01%  of all solids. 
2.3. React in unit Reactor De Dietrich DIN Reactor AE 63 via R2. Reaction occurs over 3 h. 
The final temperature of the batch is 50 C. Continuously add 949,61 ml of HCl-methanol. 
2.4. Transfer contents of unit Reactor De Dietrich DIN Reactor AE 63 to SS tank 429. 
2.5. Cool unit SS tank 429 to -30 C. The cooling time is 25 min. Continuously add 9496,09 ml 
of ISOPROPYL-ALCOHOL. 
2.6. Filter the batch from unit SS tank 429 in filter Bag Filter 100. The transfer time of the slurry 
is 30 min. Transfer 100% of the batch to the filter. The mother liquor, named Crudo de Citicolinba, 
is sent to SS tank 429. The filter separates 99,7% of all solids. The moisture content in the final 
cake is 5%. 
2.7. Transfer contents of unit SS tank 429 to Crystallizer 630. The transfer time is 10 min.3.
  
Purification 
3.1. Crystallize the batch in unit Crystallizer 630. The following components are separated in 
the crystal phase: 99,2% of CITICOLINE, 0,1% of Calcium phosphorylcholine chloride and 3% of 
Morpholidiate cytidine 5-monophosphate. The crystallization time is 125 min. Continuously add 
6566,54 g of Morpholidiate cytidine 5-monophosphate. 
3.2. Wash the column column carbon. Use 100% of the material in Crystallizer 630. The 
transfer time is 10 min. The column retains 300 ml of the solution. The solution removes 47,481% 
of the column resin contents. 
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3.3. Wash the column carbon. Use 1000 liter of WATER. The transfer time is 10 min. The 
column retains 2 liter of the solution. The solution removes 89.934% of the column resin contents. 
Spent Wash Stream: The spent wash is sent to SS tank. 
3.4. Filter the batch from unit SS tank 429 in filter Bag Filter 100. The transfer time of the slurry 
is 10 min. The moisture content in the final cake is 3%. 
3.5. Concentrate the batch in unit Bag Filter 100. The operation time is 40 min. The overhead 
is sent to Round Bottom Flask, 250 ml. Separation is: 99% of CITICOLINE goes to Bottoms. 
Unspecified materials go to Overhead. 
 
Escalade: Last step: Generic plant 
Recipe: 
1. 1st part (R1 +C1 +F1) 
1.1. Charge De Dietrich 1600 with 298.33 kg of CMP MET MORPH DCC. Charge De Dietrich 
1600 with 813.64 liter of METHANOL. Dissolve 0.1%  of all solids. 
1.2. React in unit De Dietrich 1600 via R1. Reaction occurs over 5 h. The final temperature of 
the batch is 55 C. 
1.3. Transfer contents of unit De Dietrich 1600 to ST-B. The transfer time is 10 min. 
1.4. Cool unit ST-B to -30 C. The cooling time is 35 min. 
1.5. Filter the batch from unit ST-B in filter FI-400. The transfer time of the slurry is 25 min. 
Transfer 100% of the batch to the filter. The mother liquor, named Solución 1, is sent to ST-A. 
The filter separates 99% of all solids. The moisture content in the final cake is 5%.2.  
2nd part (R2+C2+F2) 
2.1. Transfer contents of unit ST-A to De Dietrich 1600. This is the key step output. The 
transfer time is 10 min. 
2.2. Charge De Dietrich 1600 with 433.94 kg of Calcium phosphorylcholine chloride. Dissolve 
0.01%  of all solids. 
2.3. React in unit De Dietrich 1600 via R2. Reaction occurs over 3 h. The final temperature of 
the batch is 50 C. Continuously add 21.697 liter of HCl-methanol. 
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2.4. Transfer contents of unit De Dietrich 1600 to ST-B. The transfer time is 10 min. 
2.5. Cool unit ST-B to -30 C. The cooling time is 25 min. Continuously add 216.97 liter of 
ISOPROPYL-ALCOHOL. 
2.6. Filter the batch from unit ST-B in filter FI-400. The transfer time of the slurry is 30 min. 
Transfer 100% of the batch to the filter. The mother liquor, named Crudo de Citicolinba, is sent to 
ST-A. The filter separates 99,7% of all solids. The moisture content in the final cake is 5%. 
2.7. Clean unit FI-400. Cleaning time is 20 min. 
2.8. Transfer contents of unit ST-A to AT Crystallizer 10 cubic meter. The transfer time is 10 
min.3.  
Purificacation 
3.1. Crystallize the batch in unit AT Crystallizer 10 cubic meter. The following components are 
separated in the crystal phase: 99.2% of CITICOLINE, 0.1% of Calcium phosphorylcholine 
chloride and 3% of Morpholidiate cytidine 5-monophosphate. The crystallization time is 125 min. 
Continuously add 150.04 kg of Morpholidiate cytidine 5-monophosphate. 
3.2. Load the column Chromatography 100. Use 100% of the material in AT Crystallizer 10 
cubic meter. The resin retains 90% of CITICOLINE. 
3.3. Wash the column Chromatography 100. Use 4318.37 liter of WATER. The transfer time 
is 10 min. The column retains 30 liter of the solution. The solution removes 89.934% of the column 
resin contents. Spent Wash Stream: The spent wash is sent to ST-A. 
3.4. Filter the batch from unit ST-A in filter FI-400. The transfer time of the slurry is 10 min. 
The moisture content in the final cake is 5%. 
3.5. Concentrate the batch in unit FI-400. The operation time is 40 min. The overhead is sent 
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1. 1st part (R1 +C1 +F1) 
1.1. Charge Reactor 800 liter with 193,28 kg of CMP MET MORPH DCC. Charge Reactor 800 
liter with 527,14 liter of METHANOL. Dissolve 0,1%  of all solids. 
1.2. React in unit Reactor 800 liter via R1. Reaction occurs over 5 h. The final temperature of 
the batch is 55 C. 
1.3. Transfer contents of unit Reactor 800 liter to Tank SET. The transfer time is 10 min. 
1.4. Cool unit Tank SET to -30 C. The cooling time is 35 min. 
1.5. Filter the batch from unit Tank SET in filter Belt Filter 100. The transfer time of the slurry 
is 25 min. Transfer 100% of the batch to the filter. The mother liquor, named Solución 1, is sent 
to ST-C. The filter separates 99% of all solids. The moisture content in the final cake is 5%. 
1.6. Clean unit Belt Filter 100. Cleaning time is 20 min.2.  
2nd part (R2+C2+F2) 
2.1. Transfer contents of unit ST-C to De dietrich reactor 1000. This is the key step output. 
The transfer time is 10 min. 
2.2. Charge De dietrich reactor 1000 with 281,14 kg of Calcium phosphorylcholine chloride. 
Dissolve 0,01%  of all solids. 
2.3. React in unit De dietrich reactor 1000 via R2. Reaction occurs over 3 h. The final 
temperature of the batch is 50 C. Continuously add 30 liter of HCl-methanol. 
2.4. Transfer contents of unit De dietrich reactor 1000 to ST-B. The transfer time is 10 min. 
2.5. Cool unit ST-B to -30 C. The cooling time is 25 min. Continuously add 140,731 liter of 
ISOPROPYL-ALCOHOL. 
2.6. Filter the batch from unit ST-B in filter Filter P100. The transfer time of the slurry is 30 min. 
Transfer 100% of the batch to the filter. The mother liquor, named Crudo de Citicolinba, is sent to 
ST-A. The filter separates 99,7% of all solids. The moisture content in the final cake is 5%. 
2.7. Clean unit Filter P100. Cleaning time is 20 min. 
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2.8. Transfer contents of unit ST-A to AT Crystallizer 2 cubic meter. The transfer time is 10 
min.3.  
Purification 
3.1. Crystallize the batch in unit AT Crystallizer 2 cubic meter. The following components are 
separated in the crystal phase: 99,2% of CITICOLINE, 0,1% of Calcium phosphorylcholine 
chloride and 1% of Morpholidiate cytidine 5-monophosphate. The crystallization time is 125 min. 
Continuously add 97,212 kg of Morpholidiate cytidine 5-monophosphate. 
3.2. Load the column Chromatography 100. Use 100% of the material in AT Crystallizer 2 
cubic meter. The resin retains 90% of CITICOLINE. 
3.3. Wash the column Chromatography 100. Use 4000 liter of WATER. The transfer time is 
10 min. The column retains 30 liter of the solution. The solution removes 98% of the column resin 
contents. Spent Wash Stream: The spent wash is sent to ST-B. 
3.4. Filter the batch from unit ST-B in filter Filter P100. The transfer time of the slurry is 10 min. 
The moisture content in the final cake is 5%. 
3.5. Concentrate the batch in unit Filter P100. The operation time is 40 min. The overhead is 
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